Human Cytomegalovirus Vaccine Development: Progress and Prospects
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 December 2024 | Viewed by 145
Special Issue Editor
Interests: Zika virus pathobiology; cytomegalovirus pathobiology and vaccines; COVID-19 vaccines and health disparities; monkeypox; emerging pathogens
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Human cytomegalovirus (HCMV) is classified as a beta herpesvirus that undergoes latency, is ubiquitous in the general population, and can cause life-threatening disease in individuals who have a dysfunctional immune system. HCMV can cross the placental barrier and cause disease in the developing fetus. Congenital HCMV infection is highest among babies born to mothers who acquire a primary infection during pregnancy. However, acquired reinfection with a novel HCMV strain or reactivation with latent HCMV during pregnancy can lead to congenital HCMV disease. Most babies around the world with congenital HCMV disease are born to women who were seropositive prior to conception. Clinically, there are a number of antiviral medications used to treat acute HCMV disease. However, during pregnancy and under conditions of immune suppression, antivirals are not the standard of care. Therefore, the development of novel vaccines to prevent HCMV infections is vital, particularly in specific patient populations such as pregnant people, especially adolescent girls less than 20 years of age who are at risk of primary infection, the elderly, and those with compromised immune systems. Safe and effective vaccines for HCMV has been elusive; however, recent innovations in mRNA technologies and proteomics have advanced the field.
Dr. Donald J. Alcendor
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cytomegalovirus
- vaccines
- congenital
- latency
- glycoproteins
- pregnancy
- clinical trials
